GSK to Sell Stake in Haleon Valued at About $1.61 Billion
By David Sachs
GSK said it will sell its remaining stake in Haleon, ending its gradual disposal of shares in the company.
The British pharmaceutical company said Thursday that it plans to sell about 385 million ordinary shares in the London-listed consumer healthcare company, or about 4.2% of Haleon's share capital. The shares are valued at about GBP1.27 billion ($1.61 billion), based on Haleon's current market capitalization.
The price will be determined by an accelerated bookbuilding offering process that will start immediately, GSK said.
Haleon was formed in 2019 via the merger of GSK and pharmaceutical giant Pfizer's consumer-healthcare businesses into a new joint-venture, before being spun out and listed on the London Stock Exchange in 2022.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
May 16, 2024 12:28 ET (16:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth